Baillie Gifford & CO Revolution Medicines, Inc. Transaction History
Baillie Gifford & CO
- $114 Billion
- Q4 2025
A detailed history of Baillie Gifford & CO transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 194,959 shares of RVMD stock, worth $13.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
194,959Holding current value
$13.2 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RVMD
# of Institutions
364Shares Held
195MCall Options Held
2.66MPut Options Held
945K-
Vanguard Group Inc Valley Forge, PA15.7MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA14.6MShares$991 Million2.96% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$908 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.4MShares$769 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA9.81MShares$665 Million0.08% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $5.94B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...